FDA warns of serious liver injury risk with Abbvie hep C drugs

Your Health Matters

(Reuters) – U.S. health regulators on Thursday issued a warning of potential risk of serious liver injury for certain patients using AbbVie’s hepatitis C treatments, Viekira Pak and Technivie, sending the drugmaker’s shares down more than 12 percent. The Food and Drug Administration said AbbVie had identified cases of hepatic decompensation and liver failure in patients with liver cirrhosis who were taking these medicines. “Some of these events resulted in liver transplantation or death,” the agency said in a posting on its website. (Reporting by Bill Berkrot; Editing by Alan Crosby)
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave